Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed
Liquid biopsy technologies are rapidly advancing, and circulating tumor DNA (ctDNA) monitoring has demonstrated enormous potential in precision treatment for breast cancer. During the Educational Session “Adjuvant Therapy for ER-Positive Breast Cancer” at the ESMO Breast Cancer Congress (ESMO BC), Professor Heather Parsons from the Fred Hutchinson Cancer Center delivered a presentation entitled “The Role of ctDNA Monitoring in ER+ Early Breast Cancer: Could It Change Practice?”